Abnova Receives Second Large Quantity 100K Order for its EUA Approved COVID-19 Viral Extraction Kit. Abnova’s June First 100K Order Starts Shipment Out This Month

Neihu, Taiwan (July 16, 2020)

Abnova announced today that it has received a second large quantity 100K order for its EUA approved COVID-19 viral extraction kit and will starts shipping June’s first 100K order this month. The first wave of COVID-19 outbreak is unabated in the US. While the number of COVID-19 testing have increased rapidly in the US, the transmission and death rate have continued to climb in more than half of the states in the US. Viral RNA extraction is a required sample preparation procedure before the gold standard COVID-19 RT-PCR nucleic acid test.

Abnova’s current turn-around capacity for the COVID-19 viral extraction kit is about 100K order per month. Abnova can efficiently ship out the kits to the customer in the coming months. Depending on the order status, Abnova will allocate additional resources to handle the customer’s requests. Majority of the COVID-19 viral testing in the US is being performed in the clinical laboratories. Abnova expects the order to continue given the COVID-19 status in the US.

In addition to currently EUA approved COVID-19 viral extraction kit and CE-IVD approved COVID-19 human IgM IgG rapid test, Abnova is finalizing the development work for COVID-19 viral antigen test using Abnova’s own produced capture and detecting antibodies with superb sensitivity and specificity. So far, the antibodies that are used in the viral antigen test have all been developed by the Taiwan’s research institutions and sponsored by Taiwan companies for clinical testing and awaiting approval. Abnova expects to integrate its antibodies in a lateral flow point-of-care (POC) device with fluorescent detection to further maximize its detection sensitivity.